Skip to main content
 

About

WAVE Life Sciences is a preclinical genetic medicine company focused on advancing first-in-class or best-in-class stereopure nucleic acid therapies for patients impacted by rare diseases. We are utilizing our innovative and proprietary synthetic chemistry platform to design and develop nucleic acid therapeutics that precisely target the underlying cause of rare genetic diseases, with a goal of delivering new and exceptional treatment options for patients. Given the versatility of our chemistry, WAVE’s pipeline spans multiple oligonucleotide modalities including antisense, exon-skipping and single-stranded RNAi, potentially enabling us to address a broad range of therapeutic areas and diseases.

Leadership Team

Paul Bolno, M.D., MBAPresident and Chief Executive Officer

Dr. Bolno brings WAVE Life Sciences over 15 years of scientific and strategic leadership. Prior to joining as President and Chief Executive Officer, he was Vice President, Worldwide Business Development – Head of Asia BD and Investments, as well as Head of Global Neuroscience BD, at GlaxoSmithKline. He also served as a Director of Glaxo Wellcome Manufacturing, Pte Ltd. in Singapore. Dr. Bolno joined GSK as Vice President, Business Development for the Oncology Business Unit, where he helped establish GSK’s global oncology business and served as a member of the Oncology Executive Team, Oncology Commercial Board and Cancer Research Executive Team. Prior to GSK, he served as Director of Research at Two River LLC, a health care private equity firm. Dr. Bolno earned a medical degree from MCP-Hahnemann School of Medicine and an MBA from Drexel University. He was a general surgery resident and cardiothoracic surgery postdoctoral research fellow at Drexel University College of Medicine.

Michael Panzara, M.D., MPHHead of Neurology Franchise

Dr. Panzara has 15 years of biopharmaceutical industry experience developing therapies for neurological disorders. He served most recently as the Head of the Multiple Sclerosis, Neurology and Ophthalmology Therapeutic Area for Global Development at Sanofi Genzyme, where he was responsible for development strategy and oversight for compounds within these therapeutic areas. He joined Genzyme in 2009 as Group Vice President, Multiple Sclerosis and Immune Diseases, overseeing the development of Multiple Sclerosis (MS) and other inflammatory disease therapies, including the worldwide regulatory approvals of two MS drugs, Lemtrada (alemtuzumab) and Aubagio (teriflunomide). Prior to joining Genzyme, Dr. Panzara was Vice President, Chief Medical Officer, Neurology for Biogen. Dr. Panzara received his undergraduate degree from the University of Pennsylvania and medical degree from Stanford University School of Medicine. He trained in neurology at Massachusetts General Hospital, received his post-doctoral training in immunology and rheumatology at Brigham and Women's Hospital, and received his MPH from the Harvard School of Public Health.

Chandra Vargeese, Ph.D.Senior Vice President, Drug Discovery

Dr. Vargeese has over 25 years of experience in oligonucleotide research and development and has authored numerous scientific publications and patents in the field. Before joining WAVE as Senior Vice President, Drug Discovery, Dr. Vargeese served Novartis as Executive Director of Chemistry and Delivery, RNA Therapeutics Division, a position she held for over five years. Prior to joining Novartis, she led siRNA delivery in the RNA Therapeutics division at Merck & Co, where she served as Senior Director. Dr. Vargeese joined Merck through its $1.1 billion acquisition of Sirna Therapeutics, where she was Vice President of Chemistry. Before Sirna she served as Associate Director of Chemistry at NeXstar Pharmaceuticals and is the co-inventor of Macugen® (pegaptanib), an approved therapy for treating wet AMD. Dr. Vargeese earned a Ph.D. in organic chemistry at the Indian Institute of Science, Bangalore, India and completed post-doctoral work at University of Rhode Island.

Roberto Guerciolini, M.D.Senior Vice President, Emerging Franchise Head

Dr. Guerciolini has served as a Senior Vice President at WAVE since March 2015. Prior to WAVE, Dr. Guerciolini was Vice President, Emerging Business Unit at Shire AG from September 2011 to November 2014. He was Senior Vice President of Pharmaceutical Development at Dicerna Pharmaceuticals, Inc., a company he co-founded, from July 2007 to August 2011. From April 2004 to March 2007 he served as Chief Medical Officer of Sirna Therapeutics, which was acquired by Merck & Co. in 2006. Dr. Guerciolini also previously served as Senior Director of Experimental Medicine at Millennium Pharmaceuticals, as well as in clinical development roles at Hoffmann-La Roche and Schering-Plough Inc. Dr. Guerciolini received his medical degree [and Board certification in Internal Medicine] from the University of Perugia Medical School in Italy. He completed a postdoctoral fellowship in Clinical Pharmacology at the Mayo Clinic and is certified by the American Board of Clinical Pharmacology. Dr. Guerciolini additionally earned an executive MBA from the Haas School of Business, University of California-Berkeley.

Peter LaskySenior Vice President, Chief Human Resources Officer

Mr. Lasky joined WAVE in January 2016 as our Senior Vice President, Chief Human Resources Officer. Mr. Lasky has held a number of executive level HR positions within the pharmaceutical, biotechnology and medical device industries. Prior to joining WAVE, he was the Global Head of HR for Sekisui Diagnostics and before that he was the Global Head of HR for Shire Pharmaceuticals. In addition to these two roles, he has worked in senior HR positions for AstraZeneca, Millipore and the Genetics Institute. Mr. Lasky holds a B.S. in Business Administration and Industrial Management from State University New York at Plattsburgh. He has also completed various postgraduate courses and programs at the Wharton School, University of Pennsylvania, Darden School University of Virginia and Cornell University. He has spoken at various conferences and meetings on a wide range of HR topics and has served on several advisory boards including the National Science Foundation Council on Biomanufacturing Education and the Massachusetts Biotechnology Council.

Chris Francis, Ph.D.Senior Vice President, Corporate Development & Portfolio Management

Dr. Francis has over 10 years of experience in pharmaceutical and business development. Prior to joining WAVE, Dr. Francis held senior operational, strategic and business development roles within GlaxoSmithKline Oncology and was a member of the team that established GSK’s Rare Disease Unit. Before GSK, Dr. Francis was a health care private equity associate at Two River LLC. He began his career in pharmaceutical pricing and reimbursement consulting at IMS Health. Dr. Francis earned undergraduate and graduate degrees in biochemistry and molecular biology from the University of Melbourne and was a doctoral research associate at the University of Cambridge.

Keith Regnante, MBAChief Financial Officer

Mr. Regnante joined WAVE as Chief Financial Officer in August 2016. Mr. Regnante has more than 15 years of biotechnology experience and has held a number of senior financial leadership positions over that time. Prior to his current position, Mr. Regnante was a Vice President, Finance at Shire Pharmaceuticals serving on both the Finance and R&D leadership teams. Previously, Mr. Regnante held a number of positions of increasing responsibility at Biogen including leading the Corporate Finance, R&D and Business Development finance teams. During this time, he served on teams that closed a number of high-profile deals including the merger with IDEC and the in-licensing and eventual acquisitions of two multiple sclerosis drugs, TYSABRI and TECFIDERA. Mr. Regnante was also a member of Biogen's Investor Relations function and served on the team charged with responding to a proxy challenge from a major shareholder activist. Prior to Biogen, Mr. Regnante was a Consultant at The Boston Consulting Group. Mr. Regnante received his MBA from the Sloan School of Management at MIT and is a Phi Beta Kappa graduate of Tufts University where he earned his BA in Economics.

Kyle MoranVice President of Supply Chain and Operations

Mr. Moran is an executive at WAVE with over 20 years of experience. Mr. Moran joined WAVE in 2014 as Vice President, Head of Finance. Prior to WAVE, he was a founding partner at IMMP, a boutique consulting firm that provided interim CFO services to start-up and middle market companies undergoing rapid expansion or needing expert financial counsel. Prior to IMMP, Mr. Moran held senior operational and financial roles at leading global financial services firms including Zurich Scudder Investments, JPMorgan Chase and Putnam Investments. He holds a B.A. in economics from Boston College and attended the Lemberg Master’s Program in international economics and finance at Brandeis University. Mr. Moran is a Chartered Financial Analyst.

Wendy ErlerVice President, Patient Advocacy and Market Insights

Ms. Erler was appointed as our Vice President, Patient Advocacy and Market Insights in January 2016. She has a record of success in aligning business objectives with a myriad of patient advocacy and professional organizations in diverse therapeutic areas, to bring value to the business, the organizations, and to patients. Prior to joining WAVE, Ms. Erler spent 15 years at Biogen and Shire gaining experience in commercial operations, program management, and patient advocacy across a variety of therapeutic areas including oncology, ALS, MPS and SMA. She was a member of Biogen’s first rare disease business team and most recently led teams for the commercial launch in Hemophilia for Biogen. Ms. Erler earned her MBA from St. Joseph’s University and her B.A. from Miami University.

Linda Rockett, J.D.General Counsel

Ms. Rockett has nearly 15 years of experience advising management and boards of life sciences companies through some of their greatest achievements and their toughest challenges. Prior to joining WAVE as General Counsel, she was a Corporate & Securities Partner in the Life Sciences Practice at Mintz Levin. While at Mintz Levin, her worked carried an emphasis on securities and capital markets transactions, public offerings, venture capital financings, and mergers and acquisitions for life sciences companies. She also served regularly as outside general counsel, advising clients on corporate governance, risk mitigation, SEC disclosure and compliance, financings, M&A and strategic transactions, product development and commercialization, executive compensation and other matters. Ms. Rockett earned her bachelor’s degree from Tufts University and her law degree from the University of Miami School of Law. She volunteers as a Big Sister through the Big Sister Association of Greater Boston, serving as a mentor to young women.

Board of Directors

Gregory Verdine, Ph.D.Chairman, WAVE Life Sciences & President and CEO, FOG Pharmaceuticals

Gregory L. Verdine is the Erving Professor of Chemistry at Harvard University, with appointments in the Departments of Stem Cell & Regenerative Biology, Chemistry & Chemical Biology, and Molecular and Cellular Biology. He has pioneered the invention of completely new drug modalities capable of intervening in disease processes that were previously considered beyond therapeutic reach. He has also made major contributions to the understanding of innate systems in human cells that prevent the accumulation of cancer-causing mutations. Verdine holds a PhD in Chemistry from Columbia University and completed an NIH Postdoctoral Fellowship in molecular genetics at M.I.T. and Harvard Medical School. He founded a number of successful biotech companies, including Enanta Pharmaceuticals (NASDAQ: ENTA), Gloucester Pharmaceuticals (acquired by Celgene), Tokai Therapeutics (NASDAQ: TKAI) Eleven Bio (NASDAQ: EBIO), WAVE Life Sciences, Warp Drive Bio, Aileron Therapeutics, and FOG Pharmaceuticals. He also co-founded and is presently a Director of the non-profit Gloucester Marine Genomics Institute and Gloucester Biotechnology Academy, which together are catalyzing the establishment of a biotechnology cluster in Gloucester, Massachusetts. Verdine has worked in life science investing as a Special Advisor to the Texas Pacific Group and a Venture Partner at AppleTree Ventures, and he is currently a Venture Partner at Third Rock Ventures. He serves on the Board of Scientific Advisors of the National Cancer Institute and the Board of Scientific Counselors of Memorial Sloan Kettering Cancer Center.

Paul Bolno, M.D., MBAPresident and Chief Executive Officer, WAVE Life Sciences

Dr. Bolno brings WAVE Life Sciences over 15 years of scientific and strategic leadership. Prior to joining as President and Chief Executive Officer, he was Vice President, Worldwide Business Development – Head of Asia BD and Investments, as well as Head of Global Neuroscience BD, at GlaxoSmithKline. He also served as a Director of Glaxo Wellcome Manufacturing, Pte Ltd. in Singapore. Dr. Bolno joined GSK as Vice President, Business Development for the Oncology Business Unit, where he helped establish GSK’s global oncology business and served as a member of the Oncology Executive Team, Oncology Commercial Board and Cancer Research Executive Team. Prior to GSK, he served as Director of Research at Two River LLC, a health care private equity firm. Dr. Bolno earned a medical degree from MCP-Hahnemann School of Medicine and an MBA from Drexel University. He was a general surgery resident and cardiothoracic surgery postdoctoral research fellow at Drexel University College of Medicine.

Christian Henry, MBAExecutive Vice President and Chief Commercial Officer, Illumina, Inc.

Christian Henry is a diverse executive with more than 20 years of experience in growing companies in the life sciences industry. For the past 11 years Christian has been a key member of the executive team at Illumina, Inc. (NASDAQ: ILMN) where he served in a number of different roles including Chief Financial Officer, Chief Commercial Officer and General Manager of the Life Sciences Business. During his time at Illumina he helped guide the company to grow from less than $75 million in revenue to more the $2.2 billion. Prior to Illumina, Mr. Henry was Chief Financial Officer for Tickets.com, a publicly-traded online ticket provider, which was acquired by Major League Baseball Advanced Media, LP. Mr. Henry also served as Vice President of Finance and Corporate Controller for Affymetrix, Inc., (NASDAQ: AFFX), and held a similar position at Nektar Therapeutics (formerly Inhale Therapeutic Systems, Inc.). Mr. Henry earned a B.A in biochemistry and cell biology from the University of California, San Diego and an M.B.A. from the University of California, Irvine.

Peter Kolchinsky, Ph.D.Managing General Partner, RA Capital Management

Peter Kolchinsky is a founder, Managing Director, and Portfolio Manager at RA Capital Management, a crossover fund manager dedicated to evidence-based investing in healthcare and life science companies. He is active in both public and private investments in companies developing drugs, medical devices, diagnostics, and research tools, and serves as a member of the Board of Directors of Dicerna Pharmaceutics and a number of private companies. Peter also leads the firm’s outreach and publishing efforts, which aim to make a positive social impact and spark collaboration among healthcare stakeholders, including patients, physicians, researchers, policy makers, and industry. He authored “The Entrepreneur’s Guide to a Biotech Startup” and served on the Board of Global Science and Technology for the National Academies of Sciences. Peter received a Bachelor’s degree from Cornell University and a PhD in Virology from Harvard University.

Koji MiuraManaging Director, Miura & Associates Management Consultants Pte. Ltd.

Mr Koji Miura was appointed as an Independent Director of WAVE on October 23, 2012. He is currently the Founder and Managing Director of Miura & Associates Management Consultants Pte Ltd and he is an Independent Director of Azeus Systems Holdings Ltd. Prior to this, Mr Miura worked as a Japanese Consultant in the Japanese Practice Department of Peat Marwick between 1986 and 1989, where he was responsible for servicing and expanding the Japanese clientele base of the firm. He started his career with Sato Kogyo Co. Ltd, a company listed in Japan. Mr Miura holds a degree in Business Administration from the University of Aoyama Gakuin, Tokyo, Japan.

Adrian RawcliffeChief Financial Officer, Adaptimmune Therapeutics plc

Adrian Rawcliffe serves as the Chief Financial Officer at Adaptimmune Therapeutics plc and leads financial strategy, management and operations functions including financial compliance and risk management, global IT, HR and facilities. He has 17 years of experience within the pharmaceutical industry and previously served as Senior Vice President, Finance of GSK’s North American Pharmaceuticals business. Mr. Rawcliffe joined GSK in 1998 and his other senior roles at the company included Senior Vice President Worldwide Business Development and R&D Finance, where he was responsible for all business development and finance activities for GSK’s Pharmaceuticals R&D business and Managing Partner and President of SR One Ltd, GSK’s venture capital business. Mr. Rawcliffe qualified as a chartered accountant with PricewaterhouseCoopers and holds a B.Sc. degree in Natural Sciences from the University of Durham, U.K.

Ken Takanashi, MBA, CPAExecutive Vice President, Shin Nippon Biomedical Laboratories Ltd.

Ken Takanashi is an Executive Board Member at Shin Nippon Biomedical Laboratories, Ltd.(JPX:2395), a contract research organization that provides pre-clinical and clinical services for drug development to pharmaceutical and biotech companies and conducts translational research business, since 2004. Ken has experience working for more than 30 companies in the US, Japan, Singapore, China, Malaysia, India, Hong Kong, Cambodia and Bhutan and has been a board member for over 20 years, as well as establishing various biotech companies and contract research organizations. Ken received a Bachelor’s degree from the University of Tokyo and a MBA from the University of Warwick. He also has a qualification as a Certified Public Accountant (Delaware State, US).

Masaharu TanakaPresident, Kagoshima Development Co. Ltd.

Masaharu Tanaka has served on our board of directors since August 2014 and provides key business and financial experience as a venture capitalist and banker. Mr. Tanaka is the President of Kagoshima Development Co. Ltd., the general partner of Kagoshima Shinsangyo Sousei Investment Limited Partnership, or KSS. From 2013 to 2014, he was a Managing Director of the Kagoshima Lease Co. Ltd. and from 2007 to 2013, he served as the Auditing Officer of the Kagoshima Bank, Ltd. Mr. Tanaka earned his Bachelor’s degree in Commercial Science from Seinan Gakuin University.